12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

FOV2304: Development discontinued

Sanofi disclosed in its 3Q12 earnings that it discontinued development of FOV2304 to treat DME. FOV2304 was in Phase II testing for...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >